NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its first-quarter revenues increased 5 percent, with sales for its Research business "slightly higher than expected," according to President and CEO Rakesh Sachdev.

The St. Louis-based chemicals and research products firm reported total sales of $665 million for the three months ended March 31, up 5 percent from $632 million for the first quarter of 2011. On an organic basis, revenues increased 3 percent. It beat Wall Street's consensus estimate of $658.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.